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Abstract
Background: Diabetes is one of the leading causes of poor health and high care costs in Ukraine. To prevent
diabetes complications and alleviate the financial burden of diabetes care on patients, the Ukrainian government
reimburses diabetes medication and provides glucose monitoring, but there are significant gaps in the care
continuum. We estimate the costs of providing diabetes care and the most cost-effective ways to address these
gaps in the Poltava region of Ukraine.
Methods: We gathered data on the unit costs of diabetes interventions in Poltava and estimated expenditure on
diabetes care. We estimated the optimal combination of facility-based and outreach screening and investigated
how additional funding could best be allocated to improve glucose control outcomes.
Results: Of the ~ 40,000 adults in diabetes care, only ~ 25% achieved sustained glucose control. Monitoring costs
were higher for those who did not: by 10% for patients receiving non-pharmacological treatment, by 61% for
insulin patients, and twice as high for patients prescribed oral treatment. Initiatives to improve treatment adherence
(e.g. medication copayment schemes, enhanced adherence counseling) would address barriers along the care
continuum and we estimate such expenditures may be recouped by reductions in patient monitoring costs.
Improvements in case detection are also needed, with only around two-thirds of estimated cases having been
diagnosed. Outreach screening campaigns could play a significant role: depending on how well-targeted and
scalable such campaigns are, we estimate that 10–46% of all screening could be conducted via outreach, at a cost
per positive patient identified of US$7.12–9.63.
Conclusions: Investments to improve case detection and treatment adherence are the most efficient interventions
for improved diabetes control in Poltava. Quantitative tools provide essential decision support for targeting
investment to close the gaps in care.
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Background
The global burden of diabetes is enormous, with an esti-
mated 1.6 million deaths directly caused by diabetes in
2016, and another 2.2 million deaths attributable to high
blood glucose [1]. The World Health Organization
(WHO) estimates that diabetes was the seventh leading
cause of death in 2016, and projections indicate that the
burden is likely to continue growing. For Ukraine, as for
many other lower-middle income countries (LMICs),
this is placing considerable strain on already fragile
health systems [2]. Diabetes is expensive to monitor and
treat, and often occurs alongside multiple co-morbidities
that require long-term health management. Globally, the
costs associated with diabetes have been estimated at
US$827 billion annually [3, 4], or more than US$1.7 tril-
lion over 2011–2030 including indirect costs [5].
Minimizing costs of diabetes complications necessi-
tates preventing complication via early diagnosis and
consistent care and treatment. However, undiagnosed
and untreated diabetes remain significant problems glo-
bally [6]. Along the entire diabetes care pathway from
initial screening to sustained glucose control, there are
many points at which patients can be lost, or where clin-
ical outcomes may turn out poorer than desired. Late
diagnosis, as well as poor glucose control while in dia-
betes care cause serious health risks, disabilities and
costs in the health and social sectors. It is therefore im-
perative to ask whether there may be scope for improve-
ments in the delivery of services designed to guide
patients through the continuum of care. To address this
question, it can be helpful to measure what proportion
of the population has progressed to each consecutive
stage in the care continuum; this kind of cascade ana-
lysis has been effectively applied to many areas of health,
including to diabetes care in the U.S. [7] and in South
Africa [8].
In this study, we build on previous work [9] that
estimated the state of the type 2 diabetes cascade for
Poltava, an oblast (region) of Ukraine with approxi-
mately 1.4 m inhabitants, which forms part of a
World Bank support project to strengthen NCD pro-
grams in the Ukraine. This recent study identified
two key breakpoints in the cascade: case detection,
with about a third of estimated type 2 diabetes cases
missing from the diabetes register, and glucose con-
trol among HbA1C monitored patients, with only
around one in four patients achieving the glycated
hemoglobin target level of ≤7.0%. Several Ukraine
studies have identified the cost of diabetes medication
and monitoring as important barriers to diabetes care
[10–12]. Our main goals in this study are to investi-
gate options for improving these two key breakpoints
– diagnosis and glucose control – by using a math-
ematical model for optimal resource allocation.
The protocols and practices in place for the provision
of diabetes care along the type 2 diabetes cascade in Pol-
tava region are governed by the national guidelines is-
sued by the Ministry of Health in 2012 [13]. The annual
Health Index Surveys suggest that a portion of the popu-
lation does not use the care provision at health facilities,
indicating that more outreach services may be required
to find people in need of care [14]. For instance, only
34% of Poltava adults sought out-patient care in case of
sickness in 2017. Taking these protocols and survey
findings as our starting point, we: (1) gather data on the
unit costs of each of the interventions that form part of
these protocols and practices and use these to estimate
the cost of the response to type 2 diabetes in Poltava re-
gion in 2017; (2) focus on case detection, and investigate
the optimal combination of facility-based and outreach
screening; and (3) focus on adherence support interven-
tions, and investigate how additional funding could best
be allocated to get the maximum possible amount of
people with sustained glucose control.
Methods
Patient pathways through type 2 diabetes care in Poltava
region
Figure 1 summarizes the pathways through care for type
2 diabetes for both uncomplicated and complicated
cases. Screening for diabetes takes place either during
clinical visits with endocrinologists or family doctors, or
through outreach campaigns.
Individuals with a positive glucose screen require a con-
firmatory test (oral glucose tolerance test and/or fasting
glucose test) administered by an endocrinologist. Con-
firmed cases are then eligible for counseling on diabetes
management, clinical assessments, and treatment, which
can either be provided at PHC clinics or via courses run at
residential schools. Patients are either recommended for
non-pharmacological treatment (i.e., provided with dietary
and exercise advice), or prescribed with oral treatment or
insulin. In Poltava region, standard insulin was being pro-
vided to diabetes patients for free whereas the costs of oral
diabetes medications and some other insulin formulations
had to be covered by the patients (a co-payment system
for oral drugs was subsequently phased in from 2017
within the Ukraine health reform). Clinical examinations
for diabetics are provided at diagnosis and then annually,
the main ones being diabetic foot and eye examinations
by endocrinologists and ophthalmologists, respectively,
and tests for diabetic kidney disease involving nephrolo-
gists. Patients are monitored with standard laboratory
tests for plasma glucose, glycated hemoglobin (HbA1C
test) and cholesterol. Of all diabetics registered in Poltava
region in 2016, 47% were reported to have complications
(hypoglycemia, diabetic ketoacidosis, retinopathy, cataract,
gangrene, and kidney problems).
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Unit costs, coverage, and spending on interventions
We conducted a costing study in one PHC unit with
12 ambulatories and from one secondary level city
hospital to collate data on the interventions described
in the previous section. Unit costs were calculated as
bottom-up costs and included the costs of consum-
ables, salaries, and overheads, with 7% VAT added to
drugs and 20% to all other consumables. Salaries were
calculated as the average professional rate for 2018
applying to each health cadre, and the prices of con-
sumables were taken from facility invoices. The unit
costs associated with the co-payment scheme for
drugs were calculated based on the order for border
price regulation from the Ukrainian MoH (#148 from
21.01.2019). Costs were converted from Ukrainian
hryvnia (UAH) to US dollars (USD) at the mid-2018
exchange rate of 1 USD = 26.3138 UAH [15].
We then gathered estimates of coverage of each of the
interventions in 2016 using programmatic reports and
expert input gathered during a stakeholder meeting held
on 12 February 2019. We estimated 2016 spending by
multiplying the intervention unit costs by the number of
people covered by each intervention.
Mathematical model to determine best investments
across care cascade
We used the Cascade Analysis Tool or CAT (v1.4.0,
ui.cascade.tools), an open-access software application
that implements advanced analysis and optimization
methods for understanding care cascades, described in
detail elsewhere [16]. The CAT is not specific to a par-
ticular disease, but rather allows users to specify the
pathways through care and how these can be repre-
sented as a cascade. Built-in analysis methods can then
be used to answer key policy questions, e.g. estimating
how available funding should be allocated among avail-
able interventions in order to get as many people as pos-
sible with successful outcomes. The CAT is based on a
compartmental-model-type framework, which implies
that the entire population of people estimated to have
type 2 diabetes in Poltava region is divided up into one
of the states identified in the boxes shown in Fig. 1. At
each point in time, it is possible to move between these
states according to the transitions shown as arrows on
Fig. 1.
We populated the model with data on the state of the
type 2 diabetes cascade in Poltava region in 2016 [9], as
Fig. 1 Schematic indicating the pathways through care for type 2 diabetes cases in Poltava region, Ukraine
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summarized in Table S1. The flow rates between states
are influenced by (a) coverage of interventions that tar-
get these flow rates – for example, increasing coverage
of screening interventions translates to an increased rate
of flow from the “unscreened” to “screened” compart-
ments; and (b) other demographic and epidemiological
factors, such as the birth and mortality rates (summa-
rized in Table S1). By using these data in the model, it is
possible to attain estimates of the evolution of the cas-
cade under the assumption that the estimated coverage
levels do not change, and hence to construct counterfac-
tuals that investigate how the cascade would evolve
under different coverage or funding scenarios.
Estimating the optimal combination of screening modalities
Screening for type 2 diabetes in Poltava region is con-
ducted both within facilities and via outreach programs.
According to available data, 3650 new cases were detected
in 2016, with the majority (~ 3350) of these detected
through facility-based screening and the remainder (~
300) via outreach. We investigate scale-up options for
screening which would identify 5000 new cases in 2020
under differing assumptions about the positivity rate and
maximal attainable coverage of the outreach screening
modality. The target of identifying 5000 new cases is
chosen to represent a ~ 33% increase over the estimated
number of incident cases annually; attaining this target
would mean that Poltava region could begin to close the
gap between the number of prevalent cases and the num-
ber of registered cases.
To investigate options for scaling up screening, we
need to model how the average cost of screening
changes as the coverage of screening changes. For this,
we use a non-linear cost functions, reflecting the fact
that identifying new cases gets more costly as coverage
of the outreach programs increase. This type of cost
function has been used in numerous other similar math-
ematical modelling studies [17–19], and is parameterized
with two inputs: the unit cost of screening and the max-
imal attainable coverage, i.e. what proportion of the
adult population could feasibly be screened. Since the
maximal attainable screening coverage level is unknown,
we will treat it as a variable parameter, investigating
ranges between 10 and 20% for the outreach screening
modality (much of the population would not be deemed
at risk, so screening rates are unlikely to increase beyond
this). This produces a set of possible nonlinear average
total cost functions for the outreach screening interven-
tion, three examples of which are depicted in Fig. 2.
Likewise, the positivity rate of the outreach screening
is unknown, so we investigate values between 8 and
16%. These ranges are chosen based on the estimated
prevalence of type 2 diabetes in Poltava region, noting
that mass screenings are generally not cost-effective [20,
21], so outreach campaigns should be targeted toward
likely candidates, in which case the positivity rate is
likely to exceed the overall population prevalence. The
range here is also intended to account for the unknown
number of re-testers, as there is anecdotal evidence to
suggest that prevalence in outreach campaigns can be
high because of many diabetics use the outreach
Fig. 2 Illustrative average total cost curves for outreach screening programs in Poltava region, Ukraine
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campaigns as a free of charge glucose measurement. De-
tection of unique diabetes cases may therefore be lower.
Additional investments to improve glucose control
We use the CAT’s inbuilt analysis methods to investigate
two interventions that would conceivably improve glu-
cose control outcomes: the oral medication co-payment
scheme and enhanced adherence counselling at PHC
level or Feldsher posts, the lowest level facility. In each
case, we calculate the impact of scaling up the interven-
tion on the costs of meeting patient monitoring needs.
Results
Unit costs, coverage, and spending on interventions
In Table 1 we present the estimated unit costs of screen-
ing, diagnosis, treatment prescription, and enhanced ad-
herence counseling interventions, along with estimates
of the 2016 coverage levels and estimated spend. We
also present estimates of the unit costs of providing
treatment (insulin and oral) and patient monitoring
according to protocols, along with estimates of the num-
ber of people in need of each monitoring treatment and
monitoring type, and the cost of meeting those needs
(disaggregated costs are contained in Table S2).
To derive the estimates of the number of people in
need of different types of treatment maintenance, we
firstly note that around 40,000 people were linked to
care in 2016 [9]. Data from the 2018 endocrinology re-
port indicate that around 8600 people were receiving in-
sulin in 2018, and we do not expect that this number
has changed significantly since 2016. A review of the
diabetes patient files from 2016 indicates that among the
insulin patients, ~ 2/3 received insulin only and ~ 1/3
also received oral treatment. The 2016 patient files also
indicate that 8% of patients, or 3200 people, received
non-pharmacological treatment. Subtracting the insulin
patients and the non-pharma patients from the total
number of people on treatment leaves 28,200 patients
who were receiving oral treatment only, in addition to
2867 who received both insulin and oral treatment.
Table 1 Estimated unit costs of screening, diagnosis, treatment prescription, and enhanced adherence counseling interventions and
estimates of the 2016 coverage levels and estimated spend; estimates of the unit costs of providing treatment (insulin and oral) and
patient monitoring according to protocols, along with estimates of the number of people in need of each monitoring treatment
and monitoring type, and the cost of meeting those needs (disaggregated costs are contained in Table S2). Notes: (1) IEC = Information
Education Communication; (2) PHC = Primary Health Clinic
Unit cost (USD) Estimated number who received service Estimated spend (USD)
Screening tests 45,636 30,003
Facility-based blood glucose test 0.66 41,833 27,503
Outreach/community-based blood glucose test 0.66 3803 2500
Diagnosis (confirmatory test) 3344 12,708
Oral glucose tolerance tests 3.80 3344 12,708
Treatment prescription protocols 3090 8163
IEC1 through residential school/courses 5.76 773 4451
IEC through PHC2 clinic staff 1.60 2318 3712
Adherence counseling 2085
Enhanced adherence counseling at PHC clinic 0.62 2339 1439
Enhanced adherence counseling at Feldsher post 0.55 1170 646
Estimated number in need of service Cost of meeting needs (USD)
Treatment maintenance 40,000 6,097,737
Annual co-payments for oral medication 34.30 31,067 1,065,523
Annual co-payments for insulin 356.56 8600 3,066,413
Annual patient monitoring costs 40,000 1,965,801
Non-pharma, glucose controlled 24.48 960 23,504
Non-pharma, not achieving glucose target 28.28 2240 63,356
Oral, glucose controlled 25.61 8460 216,678
Oral, not achieving glucose target 52.85 19,740 1,043,278
Insulin, glucose controlled 48.97 1978 96,858
Insulin, not achieving glucose target 78.85 6622 522,126
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There are therefore an estimated 31,067 oral treatment
patients eligible for the oral copayment scheme within
the Ukraine health reform.
Patient monitoring costs are generally higher for pa-
tients who do not do well on treatment (indicated by
not attaining the glycated hemoglobin target level while
in diabetes care): 10% higher for patients receiving non-
pharmacological treatment, 61% higher for patients pre-
scribed insulin, and twice as high for patients prescribed
oral treatment (Table 1).
Mathematical model to determine best investments
across care cascade
After populating the mathematical model with the Pol-
tava type 2 diabetes data, we obtain projections of the
estimated evolution of the cascade under the assumption
that the 2016 coverage levels indicated in Table 1 are
maintained out to 2020 (Figure S1).
Estimating the optimal combination of screening modalities
The optimal screening scale-up strategy for Poltava re-
gion to identify 5000 new cases in 2020 depends on the
positivity rate and maximal attainable coverage of out-
reach screening (where ‘coverage’ here refers to the pro-
portion of adults with type 2 diabetes not already
diagnosed who are reached by the program). The more
well-targeted and scalable the outreach campaigns are,
the greater the share of screening that should be con-
ducted via outreach, as it can reach the large proportion
of people who rarely use clinics. Figure 3 displays the re-
sults regarding the optimal share of screening that
should be conducted via outreach, as well as the cost per
positive patient identified, under different assumptions
about the positivity rate and maximal attainable coverage
of outreach screening. We find that if the outreach pro-
gram cannot reach more than 10% of the population and
only 8% of screening events lead to the identification of
a new case, then conducting 10% of screening activities
via outreach campaigns (and the remaining 90% via fa-
cilities) would be the optimal strategy to minimize the
cost of identifying a new case (Fig. 3a). By contrast, if
the outreach program could reach 20% of the population
and were better targeted (such that 16% of all screening
identified a new case), then conducting 46% of screening
via outreach be the optimal strategy to minimize the
cost of identifying a new case (Fig. 3a). In the former
case, the cost per new type 2 diabetes case identified
would be USD 9.63 and in the latter it would be USD
7.12 (Fig. 3a). In general, the optimal share of screening
that should be conducted via outreach increases as the
positivity and maximal reach of the outreach modality
increase (Fig. 3b), while cost per positive patient de-
creases (Fig. 3c).
Additional investments to improve glucose control
From Table 1, we note that the annual unit cost of moni-
toring patients on oral treatment is USD 27.24 lower for
patients who have attained sustained glucose control com-
pared to patients who don’t. The cost of annual oral medi-
cation co-payments for a single patient is USD 34.30; thus,
if providing co-payments improved adherence enough to
ensure glucose control, then 80% of the oral medication
co-payment scheme could be funded by the state through
the reduction in monitoring costs alone.
Using the estimates of annual patient monitoring costs
presented in Table 1, we find that a 1 percentage point
increase in share of patients achieving sustained glucose
control would lead to a reduction in annual patient
monitoring costs of USD 10,373 in Poltava region. These
additional funds would be sufficient to increase coverage
of enhanced adherence counselling by six-fold, enabling
almost half of patients to have access to these services.
Fig. 3 a heatmaps indicating the cost of identifying a new case of type 2 diabetes, as a function of the positivity of the outreach screening
programs, the maximal attainable coverage of the outreach programs, and the share of all screening activities that are conducted via outreach
programs. The black rectangles indicate the minimum cost of identifying a new case for each level of outreach positivity and each maximal
attainable coverage level. b heatmap indicating the optimal share of screening that should be conducted via outreach as a function of the
positivity rate and maximal attainable coverage of outreach screening. c heatmap indicating the cost per new case identified as a function of the
positivity rate and maximal attainable coverage of outreach screening
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Discussion
This study represents one of the first attempts to gather
comprehensive, bottom-up costing data for health inter-
ventions related to type 2 diabetes case detection, diag-
nosis, treatment prescription, maintenance, monitoring,
and adherence. Analyzing the cascade identified two key
breakpoints, the first related to case detection and the
second to glucose control while enrolled in diabetes
care. The type 2 diabetes patient survey extracting data
from cards provided valuable information on patient
monitoring and treatment outcomes [9]. Our use of the
Cascade Analysis Tool – one of the first applications of
this software – allowed us to investigate how to balance
facility-based and outreach screening effort in order to
improve Poltava region’s efforts at case detection, as well
as to investigate how additional funding could be allo-
cated to get more people with sustained glucose control.
Increased diabetes case finding is especially important
for groups with low use of health services who miss the
screening services offered at clinic level. Data from dia-
betes screening campaigns in terms of who was actually
reached was scarce, although this represents important
strategic information to understand screening uptake
and yield by population and place. There is considerable
scope for targeted promotion of screening during the
community mobilization phase of campaigns, targeted
screening during campaigns to ensure maximum cover-
age in older persons and those with increased BMI, and
better documentation of participants profile and yield.
The literature generally discourages mass screening in
diabetes programs as the cost-effectiveness is low [20,
21]. The analyses undertaken here demonstrate the re-
quired levels of targeting and reach that outreach
screening campaigns would need to have in order to fea-
ture as a prominent component of screening scale-up
activities and improve entry into diabetes care.
More generally, type 2 diabetes case detection is of
crucial importance in numerous settings, and the
methods used in this study could usefully be applied
elsewhere. A recent review of diabetes cascades in 28
countries found the largest cascade losses at the testing
stage, with only 63.4% of those with diabetes having ever
been tested [6], which is consistent with other studies
that have reported ranges of 24–93% [6, 22–24]. A rep-
resentative population-level survey in the Ukraine which
includes biomarker assessment like blood glucose, blood
pressure and body mass would provide crucial evidence
on the burden of diabetes, the proportion not taking
medicine, and its chief co-factors high BMI and hyper-
tension. To this end, WHO’s STEPwise approach to Sur-
veillance (STEPS) survey [25] has been implemented
across Ukraine with results on disparities of the diabetes
burden across the regions forthcoming, which will help
target control efforts.
Given the extent to which patient costs pose a barrier
to effective diabetes treatment [10–12], Ukraine’s move
towards improved re-imbursement schemes for oral
anti-diabetic drugs is expected to improve glucose con-
trol levels. In order to qualify for treatment and re-
imbursement schemes, patients are obliged to be exam-
ined annually for detecting diabetes-related pathology.
Until 2017, metformin and other pre-insulin drugs had
to be paid by the patient (averaging at about US$30 per
year). The new affordable medicine schemes now offer a
set of anti-diabetic drugs free of charge in certain phar-
macies. A key improvement to be made is the availability
of regular HbA1C testing for diabetes patients to moni-
tor treatment effectiveness: although the test can be con-
ducted via the public sector without requiring an out-of-
pocket payment, supplies and access are limited, with
the for-profit private sector picking up a portion of the
additional demand (at US$4–5 per test, to be conducted
every 3 months). The cost of managing diabetes compli-
cations is partly covered by patients, with the exception
of hemodialysis. Monitoring of the care cascade will re-
veal whether the reduced patient charges for diabetes
medication encourage people to get tested and linked to
treatment. The analyses we conducted indicate that
around 80% of the costs of implementing the oral medi-
cine co-payment scheme would be covered by the result-
ing reductions in patient monitoring costs alone.
This analysis had several limitations, both on the data
and model side. On the data side: firstly, there was no
population-based biomarker survey on the prevalence of
diagnosed and undiagnosed diabetes, which would have
strengthened this analysis significantly. Secondly, dia-
betes screening was not systematically reported across
PHC and endocrinologists’ services. Thirdly, screening
campaign data lacked information about the persons
tested and found positive, and whether they were con-
firmed as diabetes cases. The routine data had the com-
mon shortfalls of patient data collected at point of
service: incomplete registration of cases, reporting num-
bers of episodes instead of numbers of persons with epi-
sodes, and laboratory data generated in the private
sector missing in patient files, while the HbA1C data
lacked information on whether they were baseline values
at diagnosis or treatment monitoring data, which would
bias interpretations on treatment effectiveness, and we
could not rule out repeat HbA1C tests being counted as
measurements in different patients. Finally, expenditure
tracking systems did not work well beyond insulin
spend, and unit costs had large uncertainty regarding
the time allocated to provide a service. On the model
side: firstly, limitations in data availability and reliability
can lead to uncertainty surrounding projected results,
and these uncertainties were not quantified. Secondly,
the model’s estimates could not be validated except by
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expert review, as there is no historical data that can be
used to verify the model calibration. Thirdly, we did not
consider the possibility of technical efficiency gains in
areas where large volumes of patients are to be served,
and which might be expected to lead to economies of
scale and reduce unit costs. Finally, the analytical part of
the study was conducted during an active phase of the
healthcare reform, meaning that some policy aspects
were uncertain. Nevertheless, we believe that the analysis
conveys a valuable picture of the continuum of care for
diabetes cases in Poltava region. As the Ukraine PHC re-
form progresses, the type 2 diabetes cascade will be re-
analyzed to determine how specific interventions have
affected care outcomes.
The Cascade Analysis Tool applied in this study is part
of a growing toolbox for supporting implementation sci-
ence, which includes approaches as diverse as return on
investment studies [26], economic cost studies [4], ma-
chine learning for prediction of disease or complications
[27, 28], and resource optimization [29].
Conclusions
Investments to improve case detection and treatment
adherence are the most efficient interventions for im-
proved diabetes control in Poltava region. For a disease
like diabetes, which has a growing burden worldwide
and consumes a significant portion of health budgets in
countries of all income categories, better analytics is in-
creasingly important so programmatic resources can be
effectively targeted.
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